Dyne launched a $300 million underwritten public offering one day after FDA acceptance and Priority Review of the z-rostudirsen BLA. An additional 30-day underwriter option could increase gross proceeds to $345 million. The timing…
Cellares and Papillon will automate manufacturing and release testing for PPL-001, an autologous gene-corrected hematopoietic stem and progenitor cell therapy for Friedreich’s ataxia. The collaboration links a systemically distributed cell-based protein-delivery strategy with Cellares’…
Agios will not advance tebapivat in sickle cell disease after a 59-patient Phase 2 trial failed to establish a differentiated hemoglobin response. Response rates ranged from 29.4% to 47.1% across three doses versus 33.3%…
Tempus AI agreed to acquire Personalis for $16.25 per share, representing an enterprise value of approximately $1.5 billion net of Tempus’ existing ownership. The deal integrates Personalis’ tumor-informed minimal residual disease testing with Tempus’…
Scribe Therapeutics set terms for an initial public offering of 7.15 million shares at $13 to $15 per share, implying approximately $100 million in gross proceeds at the midpoint. The offering would finance a…
Samsung Biologics launched an all-cash tender offer for PolyPeptide Group at CHF 44.31 per share, implying an equity value of approximately CHF 1.46 billion. The transaction is strategically important because it adds specialized peptide…
Kolon TissueGene’s allogeneic cell and gene therapy TG-C failed both co-primary endpoints in ACTiVION-II, a 531-patient U.S. Phase 3 study in knee osteoarthritis. Pain and WOMAC function improved substantially in both groups, but TG-C…
The FDA accepted Dyne Therapeutics’ biologics license application for zeleciment rostudirsen and granted Priority Review for Duchenne muscular dystrophy amenable to exon 51 skipping. The milestone places Dyne’s antibody-oligonucleotide conjugate at the center of…
Bristol Myers Squibb is expanding its NVIDIA collaboration with a second DGX SuperPOD built on eight Vera Rubin NVL72 systems. The infrastructure is intended to make large-scale AI broadly available across BMS research, from…
Nava Therapeutics disclosed $89 million in financing to advance a precision lipid-nanoparticle platform designed to deliver RNA beyond the liver, including to immune cells and kidney tissue. The company is developing in vivo CAR-T…
